

# WE HAVE ONE MISSION: END ALS.

ALS TDI moved dozens of drugs through preclinical tests, building upon a robust pipeline of potential treatments against ALS. The total number of drugs tested at our labs is now over 350—more than any other ALS research lab in the world.

---

## We are relentless.

The science team at ALS TDI:

- screened 20 potential treatments for ALS in the SOD1 mouse model.
- began studying more models of ALS in an effort to validate and characterize them.
- established a robust strategy for iPSC generation and cell-based drug screening.

---

## We are resourceful.

Through our Precision Medicine Program, our Translational Research Team initiated small molecule drug screens using neural cells derived from iPSCs.

---

## We make history.

ALS TDI became the first non-profit biotech in any disease to develop a novel potential treatment, AT-1501, and bring it from our own labs, through FDA review and into clinical trial.

---

## We collaborate.

ALS TDI partnered with Google to leverage their expertise in artificial intelligence to analyze the “big data” collected from our Precision Medicine Program, making significant strides towards the development of unbiased, quantitative and sensitive measures of ALS disease progression.

ALS TDI continued its long tradition of working with industry and academic partners to preclinically test promising drug candidates.

---

## We learn from you.

With the help of uBiome, we initiated an ALS-specific research study in which we collect five different sample types from participants to assess the possible role of the microbiome in ALS disease progression.

Learn more at [www.als.net](http://www.als.net).